The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published Friday — a finding that could ...

Ozempic, the blockbuster GLP-1 drug ... by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...

The Food and Drug Administration says it has seized several hundred units of fake versions of Ozempic. The drug maker Novo Nordisk told the FDA that the counterfeit 1-milligram injections were ...

The announcement follows new research that suggested drugs like Wegovy, Mounjaro and Ozempic slashed the risk of contracting the disease. Scientists from Israel said the drugs, also known as GLP ...

The Danish company's sales have been hit by alternative compounded versions of its Ozempic and Wegovy drugs, particularly in the U.S., a practice the U.S. Food & Drug Administration has allowed ...

The company has seen sales hit by alternative compounded versions of its Ozempic and Wegovy drugs, particularly in the U.S., a practice the U.S. Food & Drug Administration has allowed while ...